Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Autolus Therapeutics plc (AUTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 6-K Quarterly results
Docs: "6-K",
"INDEX TO CONDENSED CONSOLIDATED FINANCIAL",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress"
07/21/2023 6-K Quarterly results
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/04/2023 6-K Quarterly results
01/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Dr. Christian Itin, Chief Executive Officer of Autolus."
12/21/2022 6-K Quarterly results
12/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Underwriting Agreement, among the Company and Jefferies LLC, William Blair & Company, L.L.C. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein",
"Opinion of Cooley (UK) LLP, counsel to the Company",
"Autolus Announces Pricing of Public Offering"
12/08/2022 6-K Quarterly results
11/03/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
07/01/2022 6-K Quarterly results
06/01/2022 6-K Quarterly results
01/11/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Autolus Therapeutics announces retirement of chief financial officer and succession plan - Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, January 10, 2022 — Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that Andrew J. Oakley plans to retire from his position as chief financial officer with effect from 31 March 2022 and will concentrate on non-executive director roles. He currently serves on the Boards of Union Therapeutics A/S and Novaremed AG. Andrew will remain a senior advisor to Autolus until March 2023. Dr. Lucinda Crabtree, senior vice president of finance at Autolus, will be appointed chief financial officer following his retire..."
11/08/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Warrant issued to BXLS V - Autobahn L.P.",
"Securities Purchase Agreement by and between the Registrant and BXLS V - Autobahn L.P.",
"Registration Rights Agreement by and between the Registrant and BXLS V - Autobahn L.P.",
"Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia and advance broader platform"
11/03/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"INDEX TO CONDENSED CONSOLIDATED FINANCIAL",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS"
09/15/2021 6-K Quarterly results
06/30/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appropriately authorised independent financial adviser. If you have recently sold or transferred all of your shares in Autolus Therapeutics plc, you should forward this document and any accompanying documents to your bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or transferred only part of your holdings, you should retain these documents. The registered office of Autolus Therapeutics plc is Forest House, 58 Wood Lane, London W12 7RZ, United Kingdom. Autolus Therapeutics plc is incorp..."
05/06/2021 6-K Quarterly results
04/19/2021 6-K Quarterly results
02/11/2021 6-K Quarterly results
12/07/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1study in Adult Acute Lymphoblastic Leukemia during the 62nd ASH Annual Meeting",
"Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting",
"Slide presentation"
11/05/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2020",
"Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2020",
"Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2020"
09/18/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Sales Agreement, by and between the Company and Jefferies LLC",
"Opinion of Cooley (UK) LLP",
"Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020"
08/26/2020 6-K Quarterly results
08/06/2020 6-K Quarterly results
06/22/2020 6-K Quarterly results
05/26/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Annual Report and Accounts for the 15-month period ended December 31, 2019",
"Notice of Annual General Meeting",
"Form of Proxy"
05/07/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on May 7, 2020. We also recommend that you read our discussion and analysis of financial condition and results of operations together with our audited financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the SEC on March 3, 2020. We maintain our books and records in pounds sterling, our res..."
01/31/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers"
01/24/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Underwriting Agreement, among the Company and J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein",
"Opinion of Cooley (UK) LLP, counsel to the Company",
"Autolus Announces Proposed Public Offering in the United States LONDON - 22 January 2020 -",
"Autolus Announces Pricing of Public Offering"
11/07/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on November 7, 2019. We also recommend that you read our discussion and analysis of financial condition and results of operations together with our audited financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended September 30, 2018 filed with the SEC on November 23, 2018, or the Annual Report, and our consolidated financia..."
08/08/2019 6-K Quarterly results
05/14/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "to this Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act",
"INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on May 14, 2019. We also recommend that you read our discussion and analysis of financial condition and results of operations together with our audited financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended September 30, 2018 filed with the SEC on November 23, 2018, or the Annual Report, and our consolidated financial st..."
04/11/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Autolus Announces Pricing of Public Offering"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy